01:00 PM EDT, 05/28/2024 (MT Newswires) -- Bio-Thera Solutions and Stada Arzneimittel said Tuesday they signed a commercialization and license agreement for BAT2506, a biosimilar candidate to Johnson & Johnson's ( JNJ ) Simponi that targets tumor necrosis factor alpha.

The companies said that under the deal, Bio-Thera will be responsible for the development, manufacturing and supply of the treatment candidate, while Stada will have exclusive rights to commercialize it in the EU, the UK, Switzerland and some other countries.

Bio-Thera will get $10 million in upfront payment and up to $147.5 million in further development and commercial milestones, subject to certain conditions, the companies said.

Price: 145.18, Change: -1.79, Percent Change: -1.22